<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023633</url>
  </required_header>
  <id_info>
    <org_study_id>Oxali04882</org_study_id>
    <nct_id>NCT01023633</nct_id>
  </id_info>
  <brief_title>OPTIMOX1 in Chinese mCRC Patients</brief_title>
  <official_title>A Randomized Study Of Continuous FOLFOX4 vs. FOLFOX4 in a Stop-and-Go Fashion in 1st Line Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous OPTIMOX1 study investigated the use of oxaliplatin discontinuation and
      reintroduction in a novel stop-and-go strategy. Previously untreated patients were randomly
      assigned to either FOLFOX4 administered every 2 weeks until progression (arm A) or FOLFOX7
      for 6 cycles, maintenance without oxaliplatin for 12 cycles, and reintroduction of FOLFOX7
      for another 6 cycles (arm B). Data showed that there was no significant difference in median
      progression-free survival (PFS) and overall survival (OS) between two arms. Furthermore, this
      study showed lower Grade 3 neurotoxicity rate in arm B (17.9% vs 13.3%, P = 0.12).In order to
      investigate the efficacy and feasibility of the novel &quot;Stop and go&quot; strategy in Chinese mCRC
      patients, Prof. Shu Yongqian in JiangShu Province Hospital plans to conduct a randomized
      controlled study to compare continuous FOLFOX4 vs. FOLFOX4 in a Stop-and-Go Fashion in 1st
      Line mCRC patients. To avoid the high oxaliplatin dosage related neurotoxicity, FOLFOX4
      regimen is chosen in this study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DDC: Duration of Disease Control</measure>
    <time_frame>Oct2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS, RR, PFS, DCR, safety,</measure>
    <time_frame>Oct 2015</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: FOLFOX 4 continuous (Oxaliplatin, LV, 5-FU)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The arm A (FOLFOX4 continuous arm):receive FOLFOX4 every 2 weeks until progression or for maximum 24 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: FOLFOX4 Stop and go (Oxaliplatin, LV, 5-FU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The arm B will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, LV, 5-FU</intervention_name>
    <description>Arm B(Intervention arm) will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles.
FOLFOX4 regimen:
OXA 85mg/m2 , 2 hour infusion, d1 , Leucovorin 200 mg/m2 plus 5-FU 400mg IV bolus, then continuous 22 hour 600 mg/m2 infusion on day 1 and 2 Q2W</description>
    <arm_group_label>Arm A: FOLFOX 4 continuous (Oxaliplatin, LV, 5-FU)</arm_group_label>
    <arm_group_label>Arm B: FOLFOX4 Stop and go (Oxaliplatin, LV, 5-FU)</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed adenocarcinoma of the colon or rectum

          -  Unresectable metastases

          -  At least one bidimensionally measurable lesion of ≥ 1 cm

          -  No previous chemotherapy for metastatic disease; Completed at least more than 1 year
             oxaliplatin therapy for adjuvant treatment

          -  18-75 years old

          -  ECOG 0-2

          -  Life expectancy greater than 3 months

          -  Hemogram: WBC≥4.0 X109/L, ANC ≥2 X109/L, PLT ≥100 X109/L, Hb ≥90g/L,

          -  Adequate Renal Function

          -  Adequate Liver Function

          -  Signed informed consent before the treatment

        Exclusion Criteria:

          -  Patients with previous oxaliplatin based adjuvant chemotherapy within 1 Year

          -  Completely or partially bowel obstruction

          -  Presence of peripheral neuropathy (CTC＞grade I)

          -  Severe mental disorder

          -  CNS metastasis

          -  With other severe disease: uncontrolled active infectious disease, uncontrolled
             hypertension, heart infarction within 1 year, uncontrolled high-risk arrhythmia,
             unstable angina

          -  With other malignant disease previously or concurrently

          -  Receive other anti-tumor treatment

          -  Pregnant or lactating women, or women of child bearing potential without contraceptive
             method.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yongqian Shu, MD</last_name>
    <phone>86 25 83718836</phone>
    <phone_ext>6428</phone_ext>
    <email>shuyongqian@csco.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaofeng Chen, MD</last_name>
    <phone>86 25 83718836</phone>
    <phone_ext>6428</phone_ext>
    <email>xiaofengch198019@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital Of NanJing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaofeng Chen, MD</last_name>
      <phone>86 25 83718836</phone>
      <phone_ext>6428</phone_ext>
      <email>xiaofengch198019@126.com</email>
    </contact>
    <investigator>
      <last_name>Yongqian Shu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang University affiliated sir run run shaw hospital</name>
      <address>
        <city>HangZhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongming Pan, MD</last_name>
      <phone>0571-86090073</phone>
      <email>panhongming@tom.com</email>
    </contact>
    <investigator>
      <last_name>Hongming Pan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol. 2006 Jan 20;24(3):394-400.</citation>
    <PMID>16421419</PMID>
  </results_reference>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <last_update_submitted>December 1, 2009</last_update_submitted>
  <last_update_submitted_qc>December 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Nanjing Medical University.</name_title>
    <organization>Nanjing Medical University</organization>
  </responsible_party>
  <keyword>to investigate the efficacy and feasibility of this novel treatment strategy in Chinese mCRC patients</keyword>
  <keyword>Primary Endpoint:DDC</keyword>
  <keyword>Secondary Endpoint:OS, RR,DCR, PFS,safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

